VICL Vical Incorporated

2.38
-0.15  -6%
Previous Close 2.53
Open 2.52
Price To book 0.68
Market Cap 27136919
Shares 11,402,067
Volume 229,840
Short Ratio 4.31
Av. Daily Volume 323,572

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 4Q 2017. Eligible for Limited Use Indication Approval assuming positive data.
VL-2397
Invasive aspergillosis
Phase 2 data released September 19, 2016 did not meet primary endpoint.
ASP0113 Vaccine
Kidney transplant recipients
Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Data did not meet primary endpoint
Vaxfectin-formulated therapeutic vaccine
Herpes
Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018.
ASP0113 Vaccine
Hematopoietic cell transplant recipients

Latest News

  1. Vical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial Results
  2. Vical to Provide Company Update at BIO Investor Forum Conference
  3. ETFs with exposure to Vical, Inc. : October 11, 2017
  4. Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
  5. Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial
  6. Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
  7. ETFs with exposure to Vical, Inc. : September 14, 2017
  8. Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
  9. Edited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMT
  10. Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  11. Vical reports 2Q loss
  12. Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017
  13. Investor Network: Vical Incorporated to Host Earnings Call
  14. Vical Reports Second Quarter 2017 Financial and Operational Results
  15. Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results
  16. ETFs with exposure to Vical, Inc. : June 30, 2017
  17. Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017